PTLF (Petlife Pharmaceuticals) Retained Earnings: $-31.28 Mil (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Petlife Pharmaceuticals Retained Earnings?

Petlife Pharmaceuticals PTLF Retained Earnings is $-31.28 Mil as of Feb. 2018.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Petlife Pharmaceuticals's retained earnings for the quarter that ended in Feb. 2018 was $-31.28 Mil.

Petlife Pharmaceuticals's quarterly retained earnings declined from Aug. 2017 ($-30.39 Mil) to Nov. 2017 ($-30.86 Mil) and declined from Nov. 2017 ($-30.86 Mil) to Feb. 2018 ($-31.28 Mil).

Petlife Pharmaceuticals's annual retained earnings declined from Aug. 2015 ($-3.44 Mil) to Aug. 2016 ($-7.13 Mil) and declined from Aug. 2016 ($-7.13 Mil) to Aug. 2017 ($-30.39 Mil).

Petlife Pharmaceuticals  (OTCPK:PTLF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Petlife Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Retained Earnings Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.51 -3.44 -7.13 -30.39

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.57 -28.39 -30.39 -30.86 -31.28

Petlife Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-31.28 Mil mean?
Petlife Pharmaceuticals (PTLF) has a Retained Earnings of $-31.28 Mil as of Feb. 2018. Retained earnings is the amount of net income not issued to shareholders. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' Retained Earnings too high?
Petlife Pharmaceuticals' current Retained Earnings is $-31.28 Mil.
How does Petlife Pharmaceuticals' Retained Earnings compare to PCYN and YBAO?
Petlife Pharmaceuticals' Retained Earnings of $-31.28 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Petlife Pharmaceuticals and its competitors. Petlife Pharmaceuticals's current Retained Earnings is $-31.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Retained Earnings of $-31.28 Mil. The current Retained Earnings is $-31.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Retained Earnings is $-31.28 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.